sunitinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 2544 557795-19-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sunitinib
  • sunitinib malate
  • sutent
  • SU-011248
  • SU-010398
  • PHA-290940AD
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
  • Molecular weight: 398.48
  • Formula: C22H27FN4O2
  • CLOGP: 3
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 77.23
  • ALOGS: -4.11
  • ROTB: 7

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
July 19, 2006 EMA
Jan. 26, 2006 FDA CPPI CV

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 7897.87 42.49 2281 18114 38730 4579867
Death 4392.27 42.49 2278 18117 195885 4422712
Diarrhoea 4359.88 42.49 2077 18318 148108 4470489
Fatigue 3902.91 42.49 1909 18486 143657 4474940
Palmar-plantar erythrodysaesthesia syndrome 3399.15 42.49 859 19536 8182 4610415
Neoplasm progression 3065.58 42.49 788 19607 8067 4610530
Renal cell carcinoma 2825.92 42.49 583 19812 1909 4616688
Hypertension 2399.27 42.49 996 19399 49802 4568795
Nausea 2327.11 42.49 1458 18937 175875 4442722
Decreased appetite 2282.34 42.49 991 19404 55406 4563191
Stomatitis 2240.50 42.49 709 19686 15930 4602667
Dysgeusia 2130.44 42.49 664 19731 14155 4604442
Asthenia 2123.13 42.49 1074 19321 85089 4533508
Thrombocytopenia 2029.58 42.49 869 19526 46804 4571793
Metastatic renal cell carcinoma 2012.33 42.49 373 20022 543 4618054
Platelet count decreased 1763.12 42.49 720 19675 34282 4584315
Vomiting 1752.81 42.49 1059 19336 118640 4499957
Renal cancer 1716.26 42.49 369 20026 1541 4617056
Oral pain 1557.08 42.49 411 19984 4659 4613938
Hypothyroidism 1522.90 42.49 444 19951 7430 4611167
Yellow skin 1192.12 42.49 246 20149 798 4617799
Dehydration 1153.58 42.49 567 19828 41723 4576874
Gastrointestinal stromal tumour 1111.72 42.49 220 20175 538 4618059
Mucosal inflammation 1073.01 42.49 371 20024 10972 4607625
Anaemia 1018.62 42.49 624 19771 70936 4547661
Blood pressure increased 995.33 42.49 458 19937 29002 4589595
Pleural effusion 911.51 42.49 407 19988 23991 4594606
Weight decreased 907.34 42.49 526 19869 53938 4564659
Hair colour changes 887.17 42.49 188 20207 717 4617880
Dry skin 786.45 42.49 292 20103 10630 4607967
Ageusia 766.53 42.49 222 20173 3604 4614993
Epistaxis 747.14 42.49 332 20063 19311 4599286
Dyspepsia 740.57 42.49 311 20084 15743 4602854
Glossodynia 736.25 42.49 201 20194 2599 4615998
General physical health deterioration 733.49 42.49 369 20026 28409 4590188
Pain in extremity 710.31 42.49 477 19918 63262 4555335
Abdominal pain 704.54 42.49 464 19931 59560 4559037
Constipation 700.92 42.49 407 19988 41747 4576850
Malaise 694.46 42.49 539 19856 89618 4528979
Pyrexia 692.77 42.49 578 19817 106566 4512031
White blood cell count decreased 685.14 42.49 369 20026 32696 4585901
Blister 647.00 42.49 257 20138 11252 4607345
Neoplasm malignant 643.68 42.49 253 20142 10768 4607829
Rash 589.50 42.49 530 19865 107858 4510739
Dyspnoea 589.44 42.49 592 19803 138393 4480204
Osteonecrosis of jaw 584.79 42.49 251 20144 13396 4605201
Renal cancer metastatic 577.29 42.49 111 20284 218 4618379
Neutropenia 575.14 42.49 376 20019 47574 4571023
Bone marrow failure 558.04 42.49 238 20157 12500 4606097
Ascites 544.10 42.49 231 20164 11994 4606603
Pain 518.15 42.49 461 19934 92409 4526188
Skin exfoliation 515.49 42.49 215 20180 10672 4607925
Skin discolouration 508.47 42.49 200 20195 8518 4610079
Blood creatinine increased 492.90 42.49 277 20118 26623 4591974
Renal failure 429.98 42.49 297 20098 41072 4577525
Toxicity to various agents 426.16 42.49 370 20025 71670 4546927
Pancytopenia 417.82 42.49 242 20153 24611 4593986
Abdominal discomfort 410.80 42.49 251 20144 28157 4590440
Second primary malignancy 401.93 42.49 126 20269 2702 4615895
Pneumonia 400.40 42.49 419 19976 102396 4516201
Malignant neoplasm progression 380.51 42.49 241 20154 28795 4589802
Dry mouth 374.86 42.49 182 20213 12919 4605678
Haemoglobin decreased 374.02 42.49 263 20132 37394 4581203
Confusional state 340.49 42.49 276 20119 48558 4570039
Headache 335.79 42.49 416 19979 121957 4496640
Jaundice 332.10 42.49 165 20230 12309 4606288
Gastrooesophageal reflux disease 329.84 42.49 174 20221 14719 4603878
Hyponatraemia 323.28 42.49 205 20190 24525 4594072
Leukopenia 321.66 42.49 195 20200 21541 4597056
Oedema peripheral 319.88 42.49 250 20145 41722 4576875
Blood thyroid stimulating hormone increased 311.92 42.49 93 20302 1673 4616924
Proteinuria 307.08 42.49 129 20266 6507 4612090
Disseminated intravascular coagulation 305.30 42.49 133 20262 7340 4611257
Hyperkeratosis 294.13 42.49 86 20309 1441 4617156
Acute kidney injury 293.50 42.49 298 20097 70133 4548464
Back pain 282.98 42.49 252 20143 50347 4568250
Flatulence 275.12 42.49 127 20268 8037 4610560
Dizziness 274.43 42.49 340 20055 99531 4519066
Abdominal pain upper 273.64 42.49 212 20183 34903 4583694
Ejection fraction decreased 269.72 42.49 112 20283 5484 4613113
Oedema 264.03 42.49 163 20232 18588 4600009
Cough 258.90 42.49 250 20145 55337 4563260
Cardiac failure 257.85 42.49 185 20210 27103 4591494
Haematuria 257.64 42.49 141 20254 12829 4605768
Haemorrhage 257.02 42.49 180 20215 25382 4593215
Pulmonary embolism 253.44 42.49 201 20194 34225 4584372
Gait disturbance 252.91 42.49 206 20189 36434 4582163
Oral discomfort 252.47 42.49 81 20314 1875 4616722
Renal impairment 242.19 42.49 173 20222 25165 4593432
Product use issue 239.44 42.49 171 20224 24865 4593732
Interstitial lung disease 230.07 42.49 151 20244 19134 4599463
Dysphagia 229.60 42.49 168 20227 25363 4593234
Gastrointestinal haemorrhage 226.26 42.49 179 20216 30356 4588241
Abdominal distension 224.76 42.49 145 20250 17844 4600753
Pericardial effusion 224.04 42.49 110 20285 7988 4610609
Sepsis 222.98 42.49 205 20190 42634 4575963
Haemoptysis 221.56 42.49 113 20282 8901 4609696
Mouth ulceration 205.09 42.49 95 20300 6055 4612542
Hypotension 203.67 42.49 241 20154 67159 4551438
Erythema 195.84 42.49 189 20206 41751 4576846
Skin ulcer 195.78 42.49 97 20298 7181 4611416
Peripheral swelling 192.42 42.49 154 20241 26538 4592059
Impaired healing 190.29 42.49 100 20295 8379 4610218
Metastases to liver 187.66 42.49 87 20308 5555 4613042
Gingival pain 183.92 42.49 61 20334 1572 4617025
Skin lesion 183.86 42.49 94 20301 7439 4611158
Blood lactate dehydrogenase increased 183.04 42.49 94 20301 7509 4611088
Haematemesis 181.45 42.49 99 20296 8944 4609653
Myocardial infarction 180.51 42.49 195 20200 49181 4569416
Thyroid disorder 180.09 42.49 65 20330 2169 4616428
Chest pain 179.72 42.49 197 20198 50503 4568094
Muscular weakness 178.33 42.49 147 20248 26403 4592194
Aspartate aminotransferase increased 175.75 42.49 142 20253 24796 4593801
Alopecia 171.14 42.49 147 20248 27933 4590664
Periorbital oedema 170.63 42.49 60 20335 1853 4616744
Urinary tract infection 168.38 42.49 175 20220 42215 4576382
Multiple organ dysfunction syndrome 167.62 42.49 123 20272 18633 4599964
Cardiopulmonary failure 167.26 42.49 58 20337 1717 4616880
Aortic dissection 166.59 42.49 50 20345 920 4617677
Hypertensive crisis 165.44 42.49 74 20321 4345 4614252
Chromaturia 164.56 42.49 80 20315 5681 4612916
Product use in unapproved indication 163.64 42.49 137 20258 25136 4593461
Cerebral haemorrhage 162.10 42.49 106 20289 13335 4605262
Face oedema 161.87 42.49 83 20312 6607 4611990
Hepatic failure 159.32 42.49 104 20291 13045 4605552
Hypoglycaemia 158.38 42.49 118 20277 18291 4600306
Nephrotic syndrome 158.28 42.49 63 20332 2760 4615837
Syncope 156.80 42.49 151 20244 33244 4585353
Respiratory failure 153.58 42.49 143 20252 30183 4588414
Rectal haemorrhage 153.26 42.49 99 20296 12197 4606400
Eating disorder 151.21 42.49 66 20329 3654 4614943
Skin disorder 151.08 42.49 78 20317 6298 4612299
Skin fissures 150.95 42.49 56 20339 2022 4616575
Intestinal perforation 150.64 42.49 67 20328 3881 4614716
Cholecystitis 150.27 42.49 68 20327 4103 4614494
Arthralgia 149.13 42.49 229 20166 81765 4536832
Generalised oedema 146.04 42.49 68 20327 4383 4614214
Tongue discomfort 145.33 42.49 37 20358 356 4618241
Chills 144.13 42.49 135 20260 28704 4589893
Fall 143.37 42.49 219 20176 77827 4540770
Gingival bleeding 143.14 42.49 63 20332 3558 4615039
Insomnia 141.58 42.49 165 20230 45180 4573417
Hepatic function abnormal 141.15 42.49 100 20295 14336 4604261
Neutrophil count decreased 141.02 42.49 98 20297 13625 4604972
Muscle spasms 139.98 42.49 146 20249 35344 4583253
Hyperaesthesia 139.38 42.49 53 20342 2051 4616546
Blood bilirubin increased 138.62 42.49 94 20301 12558 4606039
Condition aggravated 135.82 42.49 183 20212 57988 4560609
Weight increased 134.54 42.49 145 20250 36436 4582161
Lipase increased 134.37 42.49 59 20336 3313 4615284
Tumour haemorrhage 133.36 42.49 43 20352 1011 4617586
Blood urea increased 133.17 42.49 80 20315 8670 4609927
Oral mucosal blistering 133.12 42.49 45 20350 1231 4617366
Metastases to lung 130.87 42.49 59 20336 3528 4615069
Metastases to central nervous system 129.12 42.49 61 20334 4063 4614534
Cardiac failure congestive 129.04 42.49 135 20260 32787 4585810
Hypoalbuminaemia 128.05 42.49 56 20339 3114 4615483
Lethargy 127.45 42.49 101 20294 17140 4601457
Hypercalcaemia 127.44 42.49 64 20331 4874 4613723
Pruritus 126.76 42.49 199 20196 72373 4546224
Performance status decreased 121.69 42.49 44 20351 1475 4617122
Oropharyngeal pain 120.67 42.49 98 20297 17221 4601376
Anal abscess 120.06 42.49 44 20351 1534 4617063
Alanine aminotransferase increased 117.78 42.49 120 20275 28253 4590344
Pancreatic neuroendocrine tumour 116.07 42.49 26 20369 135 4618462
Haematochezia 113.64 42.49 79 20316 10985 4607612
Hypophagia 113.17 42.49 69 20326 7679 4610918
Drug intolerance 112.88 42.49 104 20291 21642 4596955
Pneumatosis intestinalis 112.53 42.49 38 20357 1036 4617561
Hyperthyroidism 112.20 42.49 55 20340 3975 4614622
Thyroid function test abnormal 112.10 42.49 36 20359 835 4617762
Somnolence 110.58 42.49 143 20252 43517 4575080
Pneumothorax 110.50 42.49 60 20335 5365 4613232
Cerebrovascular accident 110.21 42.49 140 20255 41860 4576737
Glossitis 110.20 42.49 36 20359 883 4617714
Feeding disorder 110.11 42.49 47 20348 2462 4616135
Swelling face 109.82 42.49 87 20308 14753 4603844
Red blood cell count decreased 108.77 42.49 69 20326 8234 4610363
Myalgia 108.50 42.49 139 20256 41909 4576688
Blood sodium decreased 107.50 42.49 60 20335 5662 4612935
Tumour lysis syndrome 106.84 42.49 50 20345 3259 4615338
Loss of consciousness 106.62 42.49 127 20268 35555 4583042
Blood glucose decreased 106.12 42.49 60 20335 5805 4612792
Peritonitis 105.53 42.49 59 20336 5586 4613011
Intestinal obstruction 103.98 42.49 68 20327 8549 4610048
Tumour necrosis 103.59 42.49 29 20366 412 4618185
Lacrimation increased 102.99 42.49 54 20341 4499 4614098
Blood alkaline phosphatase increased 102.72 42.49 78 20317 12429 4606168
Contusion 101.70 42.49 93 20302 19165 4599432
Hypocalcaemia 101.41 42.49 65 20330 7896 4610701
Blood count abnormal 100.37 42.49 51 20344 3980 4614617
Feeling abnormal 99.71 42.49 124 20271 36281 4582316
Bone pain 99.66 42.49 79 20316 13407 4605190
Hypogeusia 99.55 42.49 28 20367 405 4618192
Mental status changes 99.04 42.49 76 20319 12300 4606297
Eye swelling 98.73 42.49 60 20335 6637 4611960
Gastrointestinal toxicity 98.28 42.49 38 20357 1539 4617058
Blood albumin decreased 96.67 42.49 48 20347 3566 4615031
Skin toxicity 96.08 42.49 39 20356 1798 4616799
Infection 95.63 42.49 121 20274 36021 4582576
Thrombotic microangiopathy 95.61 42.49 46 20349 3190 4615407
Musculoskeletal pain 95.28 42.49 84 20311 16504 4602093
Hyperbilirubinaemia 94.54 42.49 51 20344 4500 4614097
Renal cell carcinoma stage IV 94.03 42.49 18 20377 34 4618563
Oesophagitis 93.93 42.49 49 20346 4039 4614558
Hepatitis 91.26 42.49 72 20323 12133 4606464
Cardiac disorder 91.07 42.49 83 20312 17026 4601571
Cholangitis 90.27 42.49 40 20355 2295 4616302
Eyelid oedema 89.87 42.49 48 20347 4151 4614446
Hyperkalaemia 88.57 42.49 79 20316 15758 4602839
Hypoaesthesia 86.94 42.49 108 20287 31557 4587040
Tongue disorder 86.94 42.49 36 20359 1747 4616850
Haemorrhoids 85.76 42.49 48 20347 4553 4614044
Gastritis 85.34 42.49 59 20336 8127 4610470
Seizure 85.20 42.49 136 20259 50101 4568496
Burning sensation 84.42 42.49 68 20327 11804 4606793
Paraesthesia 84.17 42.49 112 20283 35021 4583576
Ileus 82.94 42.49 49 20346 5147 4613450
Thrombosis 82.16 42.49 81 20314 18323 4600274
Neuropathy peripheral 82.06 42.49 91 20304 23578 4595019
Mouth haemorrhage 82.06 42.49 36 20359 2016 4616581
Pain in jaw 81.91 42.49 59 20336 8673 4609924
Petechiae 81.51 42.49 44 20351 3887 4614710
Pulmonary oedema 80.34 42.49 73 20322 14913 4603684
Wound 80.26 42.49 46 20349 4566 4614031
Atrial fibrillation 80.19 42.49 103 20292 31112 4587485
Metastases to bone 80.08 42.49 45 20350 4301 4614296
Diverticulitis 78.64 42.49 53 20342 7004 4611593
Liver disorder 78.58 42.49 68 20327 13030 4605567
Faeces discoloured 78.24 42.49 47 20348 5090 4613507
Hiccups 78.03 42.49 34 20361 1873 4616724
Cancer pain 77.86 42.49 26 20369 684 4617913
Blood test abnormal 77.41 42.49 36 20359 2312 4616285
Melaena 77.16 42.49 60 20335 9898 4608699
Acute myocardial infarction 76.67 42.49 70 20325 14389 4604208
Colitis 76.49 42.49 61 20334 10438 4608159
Proctalgia 75.40 42.49 31 20364 1477 4617120
Clear cell renal cell carcinoma 74.77 42.49 20 20375 237 4618360
Gout 74.45 42.49 43 20352 4330 4614267
Hypertriglyceridaemia 74.25 42.49 35 20360 2318 4616279
Liver function test abnormal 73.78 42.49 69 20326 14623 4603974
Renal disorder 73.64 42.49 57 20338 9339 4609258
Bradycardia 73.51 42.49 84 20311 22485 4596112
Malignant urinary tract neoplasm 73.49 42.49 15 20380 45 4618552
Tongue blistering 72.53 42.49 22 20373 420 4618177
Therapy cessation 71.96 42.49 55 20340 8845 4609752
Cholecystitis acute 70.72 42.49 33 20362 2136 4616461
Dysphonia 70.27 42.49 58 20337 10416 4608181
Hypokalaemia 70.03 42.49 75 20320 18685 4599912
Cellulitis 69.82 42.49 71 20324 16661 4601936
Hepatic enzyme increased 69.06 42.49 73 20322 17918 4600679
Blood urine present 68.95 42.49 40 20355 4061 4614536
Sudden death 68.88 42.49 44 20351 5311 4613286
Hepatotoxicity 68.67 42.49 52 20343 8247 4610350
Rash macular 68.58 42.49 45 20350 5687 4612910
Deep vein thrombosis 68.44 42.49 86 20309 25408 4593189
Appetite disorder 68.31 42.49 26 20369 1008 4617589
Blood pressure fluctuation 68.23 42.49 39 20356 3851 4614746
Exposed bone in jaw 68.18 42.49 28 20367 1330 4617267
Cachexia 67.29 42.49 31 20364 1948 4616649
Haematotoxicity 66.97 42.49 36 20359 3153 4615444
Gastrointestinal disorder 66.74 42.49 68 20327 15993 4602604
Fluid retention 65.90 42.49 58 20337 11363 4607234
Lung disorder 65.80 42.49 60 20335 12311 4606286
Adrenal insufficiency 65.76 42.49 35 20360 3005 4615592
Blood glucose increased 65.53 42.49 82 20313 24122 4594475
Thrombotic thrombocytopenic purpura 65.53 42.49 29 20366 1658 4616939
Gingivitis 64.56 42.49 31 20364 2140 4616457
Encephalopathy 64.30 42.49 54 20341 9933 4608664
C-reactive protein increased 64.00 42.49 60 20335 12752 4605845
Oral disorder 63.57 42.49 31 20364 2214 4616383
Swelling 63.21 42.49 81 20314 24401 4594196
Cardiomyopathy 63.12 42.49 44 20351 6140 4612457
Posterior reversible encephalopathy syndrome 63.00 42.49 39 20356 4456 4614141
Tumour rupture 61.83 42.49 15 20380 116 4618481
Abdominal abscess 61.71 42.49 27 20368 1502 4617095
Joint swelling 61.12 42.49 79 20316 23999 4594598
Gamma-glutamyltransferase increased 60.67 42.49 55 20340 11199 4607398
Immune thrombocytopenic purpura 60.61 42.49 34 20361 3238 4615359
Febrile neutropenia 60.13 42.49 82 20313 26230 4592367
Renal cancer stage IV 60.11 42.49 12 20383 31 4618566
Leukoencephalopathy 59.60 42.49 28 20367 1840 4616757
Altered state of consciousness 59.53 42.49 47 20348 7924 4610673
Pancreatitis 59.46 42.49 66 20329 17112 4601485
Soft tissue sarcoma 58.93 42.49 14 20381 98 4618499
Haematocrit decreased 58.72 42.49 49 20346 8933 4609664
Purpura 58.54 42.49 35 20360 3757 4614840
Thyroiditis 58.00 42.49 22 20373 845 4617752
Left ventricular dysfunction 57.68 42.49 31 20364 2714 4615883
Chronic kidney disease 57.34 42.49 52 20343 10593 4608004
Hypersomnia 56.77 42.49 36 20359 4291 4614306
Pancreatic neuroendocrine tumour metastatic 56.74 42.49 12 20383 45 4618552
Gastric ulcer 56.57 42.49 41 20354 6082 4612515
Amylase increased 56.10 42.49 30 20365 2600 4615997
Depression 56.02 42.49 110 20285 47623 4570974
Septic shock 55.60 42.49 63 20332 16703 4601894
Transient ischaemic attack 55.33 42.49 53 20342 11569 4607028
Hyperuricaemia 54.94 42.49 26 20369 1737 4616860
Pain of skin 54.82 42.49 28 20367 2208 4616389
Feeling cold 54.18 42.49 37 20358 4994 4613603
Metastases to peritoneum 54.08 42.49 21 20374 860 4617737
Gastric disorder 53.47 42.49 39 20356 5843 4612754
Aphasia 53.05 42.49 46 20349 8834 4609763
Flank pain 52.66 42.49 29 20366 2664 4615933
Taste disorder 51.95 42.49 19 20376 658 4617939
Off label use 51.55 42.49 200 20195 128913 4489684
Pulmonary haemorrhage 51.02 42.49 31 20364 3426 4615171
Skin irritation 50.94 42.49 27 20368 2298 4616299
Cholelithiasis 50.78 42.49 46 20349 9356 4609241
Dysuria 50.45 42.49 43 20352 8067 4610530
Balance disorder 50.40 42.49 59 20336 16197 4602400
Thyroid cancer 50.20 42.49 23 20372 1427 4617170
Nasal discomfort 49.55 42.49 21 20374 1080 4617517
Abscess 49.28 42.49 34 20361 4666 4613931
Plantar erythema 48.99 42.49 12 20383 97 4618500
Skin reaction 48.98 42.49 31 20364 3682 4614915
Vision blurred 48.84 42.49 72 20323 24731 4593866
Protein total decreased 48.72 42.49 23 20372 1528 4617069
Hypomagnesaemia 48.40 42.49 35 20360 5174 4613423
Liver abscess 47.95 42.49 21 20374 1171 4617426
Pneumonitis 47.67 42.49 44 20351 9166 4609431
Hyperchlorhydria 47.14 42.49 16 20379 443 4618154
Gastrointestinal perforation 47.09 42.49 24 20371 1884 4616713
Therapy change 47.08 42.49 24 20371 1885 4616712
Weight fluctuation 47.05 42.49 21 20374 1225 4617372
Malignant pleural effusion 46.69 42.49 18 20377 723 4617874
Tenderness 46.58 42.49 28 20367 3035 4615562
Anal ulcer 46.46 42.49 14 20381 261 4618336
Brain oedema 46.14 42.49 33 20362 4794 4613803
Anal fistula 46.06 42.49 21 20374 1288 4617309
Toothache 45.82 42.49 30 20365 3776 4614821
Blood creatine phosphokinase increased 45.48 42.49 54 20341 15045 4603552
Hepatic cancer 45.44 42.49 26 20369 2571 4616026
Myxoedema 45.29 42.49 10 20385 48 4618549
Blood potassium decreased 45.13 42.49 40 20355 7906 4610691
Cardiogenic shock 45.05 42.49 34 20361 5364 4613233
Neoplasm recurrence 44.82 42.49 19 20376 978 4617619
Cytopenia 44.37 42.49 25 20370 2401 4616196
Blood magnesium decreased 43.95 42.49 24 20371 2168 4616429
Neuroendocrine tumour 43.66 42.49 14 20381 323 4618274
Acute hepatic failure 43.61 42.49 34 20361 5628 4612969
Decubitus ulcer 43.35 42.49 25 20370 2509 4616088
Retching 43.30 42.49 28 20367 3451 4615146
Cholestasis 43.26 42.49 39 20356 7881 4610716
Conjunctival haemorrhage 43.18 42.49 20 20375 1272 4617325
Oral candidiasis 43.16 42.49 28 20367 3469 4615128
Guillain-Barre syndrome 43.16 42.49 22 20373 1727 4616870
Haematoma 43.05 42.49 43 20352 9873 4608724
Musculoskeletal chest pain 42.83 42.49 29 20366 3859 4614738
Memory impairment 42.75 42.49 61 20334 20342 4598255
Pallor 42.69 42.49 38 20357 7554 4611043
Tumour pain 42.56 42.49 14 20381 351 4618246

Pharmacologic Action:

SourceCodeDescription
ATC L01XE04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:63726 neuroprotective agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Renal cell carcinoma indication 702391001 DOID:4450
Pancreatic Neuroendocrine Tumor indication
Acute hemorrhage contraindication 8573003
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Hemoptysis contraindication 66857006
Hypermagnesemia contraindication 66978005
Pancreatitis contraindication 75694006 DOID:4989
Heart failure contraindication 84114007 DOID:6000
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Posterior reversible encephalopathy syndrome contraindication 450886002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.52 acidic
pKa2 11.68 acidic
pKa3 12.32 acidic
pKa4 9.32 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR IC50 8.80 IUPHAR DRUG LABEL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 10.12 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 9.66 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Ki 7.77 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.23 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 6.96 SCIENTIFIC LITERATURE DRUG LABEL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.43 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.31 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Kinase IC50 4.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.62 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.68 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 6.54 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 5.89 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 6.05 CHEMBL
Serine/threonine-protein kinase BRSK1 Kinase Kd 5.46 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.68 CHEMBL
SRSF protein kinase 1 Kinase Kd 6.60 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.42 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.92 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 7.89 CHEMBL
Myosin-IIIb Kinase Kd 5.35 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 7.80 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.62 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 6.07 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7.70 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.89 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.70 CHEMBL
Aurora kinase A Kinase Kd 5.77 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.34 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.05 CHEMBL
Casein kinase I isoform delta Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 7.89 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 7.39 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 7.51 CHEMBL
Serine/threonine-protein kinase pim-3 Kinase Kd 5.62 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 6.46 CHEMBL
Wee1-like protein kinase Kinase Kd 5.96 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 6.17 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase BRSK2 Kinase Kd 5.96 CHEMBL
U4/U6 small nuclear ribonucleoprotein Prp4 Unclassified Kd 6.41 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6.51 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.39 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.80 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 6.22 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 5.41 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.44 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6.66 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7.03 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 7.70 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.74 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.28 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 7.26 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 7.66 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 6.48 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.60 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.96 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 6.36 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.72 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.96 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.51 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 7.77 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.80 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase 38 Kinase Kd 6.39 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.89 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.06 CHEMBL
Aurora kinase C Kinase Kd 6.66 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 8.23 CHEMBL
Casein kinase I isoform gamma-1 Kinase Kd 6.03 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 6.28 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.28 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.34 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.26 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.41 CHEMBL
Myosin-IIIa Kinase Kd 5.51 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.80 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.51 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.54 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 5.48 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.39 CHEMBL
Serine/threonine-protein kinase 38-like Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 5.57 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.54 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 6.26 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.12 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.62 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 7.18 CHEMBL
Insulin receptor-related protein Kinase Kd 6.37 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.26 CHEMBL
Serine/threonine-protein kinase pim-2 Kinase Kd 5.30 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 9 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 5.59 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.89 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.02 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.11 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.60 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 7.02 CHEMBL
Aurora kinase B Kinase Kd 6.42 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.25 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.54 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 5.24 CHEMBL
Death-associated protein kinase 2 Kinase Kd 6.82 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.62 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.44 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.85 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 7.72 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.34 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.38 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.25 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.36 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.72 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.30 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.57 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.77 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.32 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 8.26 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.66 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.96 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.74 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.36 CHEMBL
Casein kinase II subunit alpha Kinase Kd 7.09 CHEMBL
RAC-beta serine/threonine-protein kinase Kinase Kd 5.57 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.29 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.42 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.03 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.10 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.24 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.38 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.33 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 7.19 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.34 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 6.28 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.64 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 6.41 CHEMBL
SNF-related serine/threonine-protein kinase Kinase Kd 6.19 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.07 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.92 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.68 CHEMBL
Casein kinase I isoform alpha Kinase Kd 7 CHEMBL
Tankyrase-2 Enzyme Kd 5.05 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 7.20 CHEMBL
Casein kinase I isoform gamma-3 Kinase Kd 6.62 CHEMBL
Death-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.05 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.28 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.72 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 6.30 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 5.54 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.92 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.66 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.96 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.57 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.74 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.70 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 5.70 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 5.77 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.20 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.31 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.02 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.64 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 7.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.47 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.77 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.05 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.41 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.46 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.42 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.23 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.82 CHEMBL
Protein delta homolog 1 Unclassified Kd 7 CHEMBL
SRSF protein kinase 2 Kinase Kd 6.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 6.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.13 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.23 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.28 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.77 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 7 CHEMBL
Myosin light chain kinase 3 Kinase Kd 7.64 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.43 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.27 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.66 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.16 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.46 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 7.31 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.77 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 8.15 CHEMBL
Casein kinase I isoform gamma-2 Kinase Kd 6.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.52 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.48 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.49 CHEMBL
Protein kinase C alpha type Kinase Kd 5.22 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.51 SCIENTIFIC LITERATURE
Ephrin type-A receptor 7 Kinase Kd 5.62 SCIENTIFIC LITERATURE
Rhodopsin kinase Kinase Kd 6.54 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.68 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.74 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.37 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 7.26 CHEMBL
Epidermal growth factor receptor Kinase Kd 6.07 CHEMBL
Protein kinase C theta type Kinase Kd 5.37 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.26 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.80 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 7.06 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.89 CHEMBL

External reference:

IDSource
D000077210 MESH_DESCRIPTOR_UI
4025079 VUID
N0000175350 NUI
C1176020 UMLSCUI
D06402 KEGG_DRUG
421448007 SNOMEDCT_US
357977 RXNORM
421192001 SNOMEDCT_US
4025079 VANDF
d05717 MMSL
011192 NDDF
CHEMBL535 ChEMBL_ID
CHEMBL1567 ChEMBL_ID
LVX8N1UT73 UNII
341031-54-7 SECONDARY_CAS_RN
8646 INN_ID
B49 PDB_CHEM_ID
DB01268 DRUGBANK_ID
CHEBI:38940 CHEBI
5329102 PUBCHEM_CID
5713 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0550 CAPSULE 12.50 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0770 CAPSULE 25 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0830 CAPSULE 37.50 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0980 CAPSULE 50 mg ORAL NDA 20 sections